37th EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION CONGRESS
	EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION , Nice, France 17-20 September 2000
	GUEST LECTURES • Tony Raine Memorial Lecture on Cardiovascular Disease. Salt-sensitive hypertension: from gene to disease. • Angiogenesis. • Chemokine receptor blockers. • Molecular signalling of the allograft reaction and tolerance. • Endothelin and its role in renal diseases. • New aspects in dialysis amyloidosis. • Mitochondrial DNA and genetic diseases. SYMPOSIA BASIC • RENAL DEVELOPMENT AND GENETIC DISEASES OF THE KIDNEY The early stages of nephron development: - The embryonic kidney as a model system to identify developmentally regulated genes. - Nephron induction. - Development of the collecting duct. Genes involved in kidney development diseases: - WT1 gene. - Pax2 gene. - The role of nephrin in the glomerulus development. New insights in the pathophysiology of cystic kidney diseases: - Mechanisms of cyst formation. - Polycystin-1 and polycystin-2 interaction partners. - The pathophysiologic role of nephrocystin. • BIOLOGY OF RENAL CELLS: INFLAMMATION, REPAIR AND PROGRESSION Mediators of tissue remodeling: - SMADs in TGFb signalling. - The role of thrombospondin. - Lessons from thrombin receptor deficient mice. Renal cell cycle regulation and apoptosis: - Cell cycle protein in glomerular diseases: new targets for therapeutic intervention. - Cell cycle proteins in renal tubular cells and diabetic nephropathy. - Apoptosis in renal diseases. Podocyte biology and the glomerular filter: - Synaptodotin and podocyte structure. - Pathways of podocyte injury. - Podocyte transdifferentiation in glomerular diseases. • ION WATER TRANSPORT AND HAEMODYNAMICS: FROM GENE TO DISEASE Organic solute transport in proximal tubule: - Amino-acid transport and genetic diseases. - Organic anion transporters. - Organic cation transporters. Renin release and haemodynamics: - Renal haemodynamics and hypertension. - Renin release and hypertension. - Angiotensinogen as candidate gene in human essential hypertension. Calcium chloride and magnesium transport in stone formation: - Calcium channel and genetic diseases. - Chloride channel and genetic diseases. - Calcium sensor and genetic diseases. GENERAL NEPHROLOGY Advanced glycated end-products (AGE) in Nephrology and Hypertension: - AGE’s in uraemia. - AGE’s and vascular remodelling. - AGE’s and diabetic angiopathy. Target blood pressure: what is the controlled evidence ? - The J-curve phenomenon; what remains in the year 2000. - Abnormal circadian blood pressure profile; lessons from diabetes mellitus. - Is blood pressure the only relevant parameter for the titration of antihypertensive therapy ? Immunological monitoring and therapeutic approaches in glomerular diseases: - Immunological approaches and methodologies. - T cell frequency and immunological monitoring. - Gene therapy: darkness and brightness. IgA nephropath: how to treat ? - Current understanding of the pathogenesis. - ACE inhibitors. - Steroids and Omega 3 lipids. Role of inflammation in cardiovascular disease of Chronic Renal Failure: - C reactive protein (CRP) as a marker of inflammatory state and cardiovascular prognosis. - Role of superoxide dismutase in the pathogenesis of atherosclerosis. - Mechanisms of lipid and lipoprotein oxydation and vascular consequences. New advances in the pathophysiology of haemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP): - Current knowledge on HUS. - The role of factor H deficiency in HUS. - The role of von Willebrand factor-cleaving protease in TTP. Essential hypertension: is it always idiopathic? - Central nervous system causes of hypertension. - Normokaliemic hypermineralocorticism in clinical practice. - Glucocorticoid-related hypertension. DIALYSIS Influence of late referral on Dialysis survival: - Optimal referral of renal patients. - Deleterious effects of late referral on dialysis survival. - Effects of late referral on the choice of dialysis modality. New insights in the pathogenesis of peritoneal membrane alterations in long-term Peritoneal Dialysis: - Glucose in the pathogenesis of membrane alteration. - Peritonitis and length of dialysis. - Advanced Glycation Endproducts (AGE’s) related changes. How to improve Haemodialysis outcome: - Biocompatibility. - Clearances. - Flux. How to improve long-term outcome in Peritoneal Dialysis: - Solutions and fluid status. - Adequacy and prescription. - Long-term survival as compared to Haemodialysis. Role of calcium and phosphate metabolisms in cardiovascular complications in uremia: - Assessment of calcifications of cardiac / vascular structures. - PTH and arterial distensibility / cardiomyopathy. - Treatment / prevention of cardiac / vascular calcifications. How to treat very elderly (75 +) patients by dialysis: - Why to treat the very elderly and specific problems. - Peritoneal dialysis in the very elderly patients. - Hemodialysis in the very elderly patients. Quality of life (QOL) in ESRD patients: - Evaluation tools for QOL. - Patient and treatment factors related to QOL. - QOL as a predictor of morbidity and mortality. TRANSPLANTATION Renal transplantation in the elderly patients (65 +) : problems and new approaches: - Impact on mortality / morbidity of renal transplantation in the elderly recipients. - How to prevent / minimize cardiovascular disease after renal transplantation. - Which immunosuppression for elderly recipients who received kidneys from older donors ? Rare viral infections in transplant patients: HHV6, HHV8 and polyoma-viruses (BK and JC Viruses): - Spectrum of HHV6 infection. - HHV8 infection and oncogenesis: Kaposi sarcoma, Castelman disease, ... - Polyomavirus hominis 1/2 (BK and JC viruses) in immunocompromised host. Results of the large randomized trials with the new immunosuppressive regimen: - Prograf vs Neoral in a triple therapy regimen. - Sirolimus vs Neoral in association with MMF + steroids. - MMF in renal transplantation. The use of cloned organs for xenotransplantation: - Basics of xenorejection. - Target molecules and production of cloned organs. - Experimental protocols and results in primates. De novo glomerular lesions in renal transplantation: - Glomerular lesions observed in chronic rejection: transplant glomerulopathy. - Viral-related glomerular diseases. - Other de novo GN occuring in recipients whose original disease was not a chronic GN. Usefullness of baseline / protocol biopsies in renal transplantation: - Value of baseline biopsies. - Critical approach to protocol biopsies. - How to manage discrepancies between clinical and pathological data. Use of non-heart beating donors in renal transplantation: - Social, ethical and legislation aspects. - The organisation of a specific programme: pratical experiences. - Results obtained with non-heart beating donors kidneys. FORUM: EUROPEAN BEST PRACTICE GUIDELINES for • Renal Transplantation • Chronic Peritoneal Dialysis • Chronic Haemodialysis CONTROVERSIES • Classical induction therapy vs no induction as initial immunosuppressive protocol ? • Should anti HCV-positive dialysed patients be isolated ? • Should Peritoneal Dialysis be the first dialytic treatment for ESRF ? CME COURSES / WORKSHOP •Peritoneal dialysis: - Adequacy and prescription. - Peritoneal access and peritonitis. - Management of ultrafiltration failure. •Pathology of the transplanted kidney: - The revised Banff criteria. - Application / Adequation for acute and chronic rejection. - Application / Adequation for glomerular lesions. •Is it possible to slow progression of renal disease? - Mechanisms for self progression of renal diseases. - Diet and slowering of progression. - ACE inhibitor therapy and slowering of progression. •Molecular analysis of renal biopsy and urine (workshop): - Studying individual glomerular cells in human renal biopsy. - Analysis of gene expression in individual glomerular. - Exploring the expression of genes by differential substractive hybridization. 2 CLINICO-PATHOLOGICAL CONFERENCES
	Organized by:	EUROPEAND RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
	Deadline for Abstracts:	03/03/2000
	Registration:	CONGRESS PRE-REGISTRATION RULES Delegates Registration fee entitles the delegate to attend all Scientific and Poster Sessions, Opening Ceremony, Welcome Cocktail, Industrial Exhibition, and to receive congress kit (including Abstracts Book and Certificate of Attendance) and coffee tickets. Each delegate must fill in a separate form. For additional forms please print it from the FORMS section or contact the ERA-EDTA Congress Office. Accompanying guests • Accompanying guests’ registration fee includes admission to Opening Ceremony, Welcome Cocktail and a half-day excursion. • Please be informed that accompanying guests are not entitled to attend any of the other Congress initiatives (i.e. Industrial Exhibition, Session and Poster Halls). • Accompanying guests’ registration is accepted only in connection with delegate’s registration. • Children under the age of 12 cannot be registered as accompanying guests. They can be admitted to social functions, only if accompanyied by regularly registered adults, and their number must be limited to one child per registered adult. They will not be permitted in the exhibit/poster/session halls at any time. Pre-Registration instructions • Fill in the form and send it to the ERA-EDTA Congress Office, together with the Payment (credit card details, cheque or copy of transfer receipt issued by the bank). • In order to benefit of the Pre-Registration fees, forms and payments must be received within the deadlines. • Please clearly indicate your name, address and ERA-EDTA XXXVII CONGRESS on cheques and money orders. Do not forget to send the Pre-Registration form completely filled in. • Make sure that you send your Pre-Registration form and payment in time, otherwise you will not be able to take advantage of the reduced fees after the deadlines or it will be impossible to include your name in the Pre-Registered Delegates’ list. • Pre-Registration forms received without payment or proof of payment will not be processed. No exceptions will be made. • Membership and payment of ERA-EDTA and/or EKRA membership fees will be verified for all individuals who indicate they are ERA-EDTA and/or EKRA members. • The reduced early Pre-Registration fee for ERA-EDTA and/or EKRA members (i.e. 250 Swiss Francs/157,50 Euros), which must be received by April 28, 2000, is nominal and NOT refundable in case of cancellation. • If you send your Pre-Registration form by fax with a credit card payment, do not also mail a copy, since it may result in a duplicate registration and charged twice. • After July 28, 2000, only On-Site Registration will be possible. On-site forms will be available in the registration area of the Acropolis Congress Centre in Nice, starting September 17, 2000. • No anonymous bookings will be accepted. • A confirmation letter will be sent to regularly pre-registered delegates to the address written in the form approximately one month prior to the Congress. • Receipts or written confirmations of payment are not automatically sent. If you wish to receive a receipt of the payment, clearly state this when sending the form and payment. NO NAME SUBSTITUTIONS ARE POSSIBLE. Cancellation policy Before July 28, 2000 75% of the amount paid will be reimbursed (with the exception of the early ERA-EDTA and/or EKRA member’s pre-registration fee) After July 28, 2000 no refund of the Amount paid • All cancellations must be done in writing and must be received within July 28, 2000. • All refunds, if any, will be done after the Congress. Delivery In order to avoid any misplacing, please make sure that the Pre-Registration form is sent to the correct address/fax below: ERA-EDTA Congress Office, Casella Postale 474 Parma Sud, 43100 Parma, Italy, Fax: ++39-0521-291777. For Courier Delivery: ERA-EDTA Congress Office, Via Spolverini 2, 43100 Parma, Italy ERA-EDTA will not be held responsible towards forms and payments sent to other offices or to a wrong address or fax number. ON-SITE REGISTRATION (please read this carefully after July 28, 2000) The On-Site Registration fees will be the following: ERA-EDTA and/or EKRA Member (who has regularly paid the membership fee) CHF 520/Euros 325,50 Non-Member CHF 700/Euros 441 Accompanying guest CHF 100/Euros 63 • Forms will be available at the Acropolis Congress Centre starting September 17, 2000. • It will be possible to pay by bank cheque, bank transfer (in which case a copy of the bank transfer receipt issued by the bank must be handed in together with the form), cash and credit card (Visa, Eurocard/Mastercard or American Express). •The equivalent in French Francs will be accepted for On-Site Registration at the exchange rate of September 15, 2000. The exchange rate will be posted (on September 17) in the Registration Area. Please note that all payments by credit card will be charged in Swiss Francs. • Please note that after July 28, 2000, you will not be included in the pre-registered list, even though the payment has been sent: credit cards will not be cashed and a copy of cheques or transfer receipts issued by the bank must be given at the On-Site registration desk together with the On-Site form completely filled in. If the late pre-registration fee is paid (by cheque or bank transfer), the on-site fee must be assessed and the difference according to the on-site rates must be paid.
	Email for Requests and Registration:	eraedta@unipr.it
	Posted by: Francesca Trebelli   Host: 212.216.163.233 date: January 25, 2000 8:38:17 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.